Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LY03003 vs Neupro in Healthy Volunteers
NCT03733561Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Nov 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Rotigotine extended-release microspheres in Parkinson's disease (PD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Maximum Plasma Concentration at 34 days. Started Nov 2018; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03733561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733561.